Clinical Trial

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-05-29; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2024-08-13
Trial Details
NCT Number NCT06435260
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Pancreatic Cancer
Enrollment 30 participants
Start Date 2024-08-01
Primary Completion 2025-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-06